Innovator’s Business Series
The Innovator's Business Series features talks and informal discussions with thought leaders from academia and industry focused on best practices in translational science. Speakers present the perspective of successful innovators in translating scientific advances into public value. The theme of the series centers on the need for integrating technological and business innovation in the fields of biotechnology, healthcare, high-tech and alternative energy.
The Congresswoman visited Bentley University for an important discussion about innovation in the biopharmaceutical industry with members of Bentley's faculty and local biopharmaceutical executives.It was a great opportunity to participate in a discussion of the government’s contribution to the basic science that leads to new medicines, and how the industry translates this science into innovative products and successful companies.
In 2017, Biogen launched Spinraza, an innovative medicine for the treatment of Spinal Muscular Atrophy (SMA), a fatal disease of children. Spinraza was the first of a revolutionary class of drugs termed antisense therapeutics. In 2018, Spinraza is expected to generate over $1.5 billion in revenues for Biogen and their partner, Ionis Pharmaceuticals. Bentley alumnus Lance Colwell ’92, former Vice President for the U.S. Rare Disease Group at Biogen, and Wildon Farwell, Senior Medical Director of Clinical Development at Biogen, discussed the commercial launch of the revolutionary new product, Spinraza.
After 25 years of anticipation, the first gene therapy product was approved in 2017. This is an amazing time in gene therapy and uniQure is a leader in the field. uniQure’s Chief Executive Officer, Matt Kapusta, will talk about creating transformative therapies for patients with rare diseases and the process of bringing innovative cures to market.
Professor Calestous Juma of the Harvard Kennedy School, joined us to discuss his recently published book, Innovation and Its Enemies: Why People Resist New Technologies, as part of our Innovator's Business Series.
Read the feature piece: Here's Why People Resist New Technologies
Bentley University’s Center for the Integration of Science and Industry continued its lecture series “The Innovator’s Business,” hosting a panel discussion about the development of the world’s most successful medicine (Humira) in Worcester which exemplifies the power of effectively integrating science, business, and policy to develop therapies that change lives. Three critical contributors to this fusion discussed this landmark success of translational science: Governor Dukakis, Dr. Robert Kamen, and Mr. Robert Anderson. Robert Coughlin summarized the implications for today's biopharmaceutical industry.
Bentley University’s Center for the Integration of Science and Industry continued its lecture series “The Innovator’s Business,” hosting speaker Sandra Fenwick who spoke about Innovation in 21st Century Healthcare; The Boston Children's Hospital Experience.
Bentley University’s Center for the Integration of Science and Industry continued its lecture series “The Innovator’s Business,” hosting speaker Dr. Donald Berwick who spoke about The Business of Healthcare Reform: What it looks like and what we should do.
Bentley University’s Center for the Integration of Science and Industry continued its lecture series “The Innovator’s Business,” hosting speakers Nigella Hillgarth, Brian Helmuth, Ronald Stotish, Michael Jay Walsh, and Joshua Boger who spoke about the potential and challenges of new technologies in protecting oceans, coral reefs and fisheries while providing food and energy for a growing population.
A fireside chat with Barry Werth, Author of The Billion Dollar Molecule and The Antidote. Moderated by Aaron Nurick, author of The Good Enough Manager.
For two decades, acclaimed author, journalist, and historian Barry Werth had unprecedented access to the inner workings of Vertex Pharmaceuticals. Werth described Vertex’ founding as a venture-based start-up company in his book The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now in The Antidote, he returns to tell the riveting story of Vertex’s two decade quest to discover and develop breakthrough medicines and the company’s stunning success. More real than any case studies, Werth’s books capture the broad scope of what it really takes to build a 25-billion dollar company.
The Center for Integration of Science and Industry at Bentley University focuses on understanding, and accelerating the translation of scientific discoveries for public value. Researchers from the Center described insights from the Center’s first two years, including measures of the value provided by translational science, use of a novel TIMETM metric to assess technological readiness for innovation, as well as strategies to improve the value created by advances in biomedicine and energy research. Speakers included Fred D. Ledley, MD, Laura McNamee, PhD, and Michael J. Walsh, PhD. Nancy Hsiung, PhD, served as rapporteur and discussed how the Center’s work can impact industry.
Bentley University’s Center for the Integration of Science and Industry continued its lecture series “The Innovator’s Business,” hosting key-note speaker Josh Boger who spoke about "Managing in Balance" and the underlying business principles to manage businesses in a sustainable and socially responsible manner. Examples discussed included Vertex Pharmaceuticals and Wesleyan University.
The Center for Integration of Science and Industry co-hosted key-note speaker Nick Donofrio, Executive Vice-President for Technology and Innovation, IBM (retired) as part of the Innovator's Business Series. Nick Donofrio is a 44-year IBM veteran who lead IBM's technology and innovation strategies from 1997 until his retirement in 2008. To learn more about 21st Century Innovation and view a video of the talk, click the link below.
Bentley University’s Center for the Integration of Science and Industry, Center for Women and Business, and WEST continued the fall lecture series, "The Innovator's Business" with Dr. Deborah Dunsire, President and CEO Envivo Pharmaceuticals. Deborah Dunsire, MD, is an industry leader with 25 years of scientific, clinical, operational and commercial experience, and proven leadership in the bio-pharmaceutical industry.
Read the Boston Business Journal article “Pharma CEO Deborah Dunsire shares career advice at Bentley”
Bentley University’s Center for the Integration of Science and Industry, kicked off its fall lecture series, “The Innovator’s Business” with key-note speaker Susan Windham-Bannister, PhD, President and CEO of Massachusetts Life Sciences Center on October 17, 2013.
On February 27, 2013 three inventors of groundbreaking technologies that have created multi-billion dollar markets, talked about the path from invention to product success. Speakers included:
Dr. Michael Boss, whose method for producing monoclonal antibodies enabled a new class of drugs that has revolutionized the treatment of cancer and other diseases, and currently represent a >$20 billion market.
Dr. David Fischell, whose invention of drug coated stents revolutionized the treatment of heart disease and created a >$4.5 billion market.
Dr. Frank Szoka, whose invention of liposome nanoparticles enabled improved targeting of cancer cells and created a >$2 billion market.
They were joined by experienced entrepreneurs and business executives Dr. Allan Green and Mr. Bruce Leicher, Esq., who spoke and lead a discussion of strategies for creating successful products and businesses from scientific invention.